Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 876 across all filing types
Latest filing 2026-05-25 AGM Information
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
Chair's Address and CEO Presentation 22 pages 2.0MB
AGM Information Classification · 92% confidence The document is an ASX announcement titled “Chair’s Address & CEO Presentation” and includes the full Chair’s address and CEO slide deck for the Annual General Meeting on 26 May 2026. It constitutes presentation materials shared at the AGM rather than a standalone earnings release, regulatory filing or proxy, fitting the definition of AGM Information (AGM-R).
2026-05-25 English
Investor Webinar Presentation 13 pages 1.2MB
Investor Presentation Classification · 93% confidence The document is an ASX announcement attaching a slideshow for an investor webinar on the upcoming Phase III interim analysis of Avecho’s CBD insomnia trial. It is a detailed presentation (with slides, trial design, endpoints, milestones) intended for investors, not an earnings summary, financial statements, or formal regulatory filing. Therefore it best fits the Investor Presentation category.
2026-05-24 English
Resignation of Non-Executive Director 2 pages 135.0KB
Board/Management Information Classification · 90% confidence The document is an ASX announcement solely about the resignation of a non-executive director and withdrawal of a resolution from the AGM notice. It outlines a board change and steps taken under listing rules. This is a Board/Management Information announcement rather than the AGM materials, proxy documents, or financial results. Therefore it should be classified as a management/board change filing.
2026-05-24 English
Receipt of Research & Development Tax Incentive 3 pages 138.8KB
Regulatory Filings Classification · 85% confidence The document is an ASX announcement disclosing the receipt of a government R&D tax incentive. It does not present financial results (Earnings Release), a capital raise or debt issuance (Capital/Financing Update is for financing from investors or debt markets), nor governance or board changes. It’s a general regulatory market announcement that does not fit a more specific category, so it falls into the fallback “Regulatory Filings” (RNS) category.
2026-05-21 English
Avecho completes treatment for Phase III interim analysis 4 pages 162.4KB
Regulatory Filings Classification · 89% confidence The document is an ASX announcement providing a corporate update on the completion of the treatment phase for an interim analysis in Avecho’s Phase III clinical trial. It does not contain actual financial statements, earnings data, management/board changes, dividend or share issuance details, nor is it an investor slide deck. Rather, it is a general regulatory announcement to the market that does not fit into the more specific categories. Therefore, it falls under the fallback category Regulatory Filings (RNS).
2026-05-20 English
Application for quotation of securities - AVE 7 pages 21.2KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX Appendix 2A filing (“Application for quotation of securities”) detailing the conversion of options into new shares and the application to quote these additional securities. It is not a financial report but an announcement of a capital change (new share issuance). This matches the “Share Issue/Capital Change” category.
2026-05-12 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.